MEDIPOST Co., Ltd. (KOSDAQ:078160)
19,110
-890 (-4.45%)
At close: Dec 5, 2025
MEDIPOST Revenue
MEDIPOST had revenue of 18.69B KRW in the quarter ending September 30, 2025, with 8.18% growth. This brings the company's revenue in the last twelve months to 73.59B, up 5.33% year-over-year. In the year 2024, MEDIPOST had annual revenue of 70.66B with 2.93% growth.
Revenue (ttm)
73.59B
Revenue Growth
+5.33%
P/S Ratio
10.15
Revenue / Employee
228.53M
Employees
322
Market Cap
746.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 70.66B | 2.01B | 2.93% |
| Dec 31, 2023 | 68.64B | 4.44B | 6.92% |
| Dec 31, 2022 | 64.20B | 9.34B | 17.03% |
| Dec 31, 2021 | 54.86B | 6.23B | 12.82% |
| Dec 31, 2020 | 48.62B | 2.81B | 6.14% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.14T |
| Hanmi Pharm. | 1.47T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| LigaChem Biosciences | 159.27B |